

Electronic Acknowledgement Receipt

EFS ID:	7717842
Application Number:	09993647
International Application Number:	
Confirmation Number:	1010
Title of Invention:	omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
First Named Inventor/Applicant Name:	Bernd Riedl
Customer Number:	23599
Filer:	Csaba Henter
Filer Authorized By:	
Attorney Docket Number:	BAYER 18A
Receipt Date:	01-JUN-2010
Filing Date:	27-NOV-2001
Time Stamp:	13:15:36
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	P17- BERGESTEPHENMLYLEDBIGHLE YANDDONALDCMONKHOUSEP HARMACEUTICALSALTS.pdf	2779981 24d4aa003e1a22d855791f541addbf10ad26540d	no	19

Warnings:

Information:

2	NPL Documents	P18-Bergstralh-MicrotubuleStabilizingAgentsTheirMolecularSignalingConsequences.pdf	1440893	no	14
			efe0ca68a222158b8dddf2ec4492261cbdd437a4		
Warnings:					
Information:					
3	NPL Documents	P19-BERTRANDFEETALINHIBITIONOFFPI3KMTORANDMEKSIGNALINGPATHWAYS.pdf	438413	no	5
			41e44cd095ced82a23a8fede6e54fab521342a713		
Warnings:					
Information:					
4	NPL Documents	P20-BHAGWAT-AngiogenicRegulatorCD13APN.pdf	1157025	no	9
			ab5816af95920ab9a0fa0c960004c969210b14e0		
Warnings:					
Information:					
5	NPL Documents	P21-BIANCHIETAL-MulticenterUncontrolledTrial.pdf	1439972	no	33
			81ef8db8730fcd2785cc408f46546a4c47a83fe8		
Warnings:					
Information:					
6	NPL Documents	P22-Martin-Blanco-p38MAPK.pdf	212665	no	9
			9b6d919d8ea7158136b66ceac569b372bb7c71781		
Warnings:					
Information:					
7	NPL Documents	P23-Foussard-Blanpin-ComparitivePharmacodynamicstudy.pdf	324049	no	12
			7673a4217ac16d6b526a4a4745c2b0a443dd47d8		
Warnings:					
Information:					
8	NPL Documents	P25-BOLLAGETAL-RAFPathwayInhibitors.pdf	570524	no	6
			124e6f8014aca1cad11e69dc70a8191a0db759e8		
Warnings:					
Information:					
9	NPL Documents	P26-BoltonetalOncogeneDirectedApproachesinCancerChemotherapy.pdf	1322358	no	10
			3d861bca2a7bd236e2a3b2f6a645b585b7b14221		
Warnings:					
Information:					
10	NPL Documents	P26a-Bono-et-al-Blood-v103-n8-p2929.pdf	481721	no	7
			17dde6c8e25ee5d3f11202b97142bd4c0cc2d0f		
Warnings:					
Information:					

11	NPL Documents	P24-BOARD ETAL-PlateletDerivedGrowth.pdf	948188	no	10
			b4f08ac5c7c822fd84b547b8e36f858031a9cb00		
Warnings:					
Information:					
12	NPL Documents	P24a-Bok-Cancer-Res-v61-p2533.pdf	896719	no	4
			71d8b16e21fe97a365438dc5dceda95a580daceb		
Warnings:					
Information:					
13	NPL Documents	P27-BosrasOncogenesisinHumanCancerAReview.pdf	903184	no	8
			93fba15bb2c81caa83602dc55926b1018b8b9db		
Warnings:					
Information:					
14	NPL Documents	P28-Boulton et al Heterocyclic Rearrangements Part X A Generalised Monocyclic Rearrangement.pdf	524828	no	4
			46aec3f3ca8ffbe790b3d6bf065c03af7fca024c		
Warnings:					
Information:					
15	NPL Documents	P28a-Boyer Small Molecule Inhibitors of KDR.pdf	2453975	no	28
			41b072c857def1b0cfea15ffe6e34f525f878b9c		
Warnings:					
Information:					
16	NPL Documents	P29-BOYD DER EKETAL ARENEOXIDES OF QUINOLINE.PDF	374690	no	4
			97aad8c9cd3cfbae0671bb76205411406e98d43e		
Warnings:					
Information:					
17	NPL Documents	P29a-Braybrooke-et-al-Clin-Cancer-Res-v6-n12-p4697.pdf	1546108	no	8
			d7c3b8fa1e41c694cb43ad44d394285cbd6af8c5		
Warnings:					
Information:					
18	NPL Documents	P29b-Broll-et-al-Eur-J-Surg-Oncol-v27-n1-p37-1.pdf	1706850	no	6
			fd938158c516dac7a0096b52a95f67ec8094ca37		
Warnings:					
Information:					
19	NPL Documents	P30-Bruder et al Adenovirus Infection Stimulates the Raf MAPK Signaling Pathway.pdf	752028	no	7
			c058bfdd8530d768880ec4a34659bf9b29781a1		
Warnings:					
Information:					

20	NPL Documents	P31- BUNDGAARDHANSDESIGNOFF RODRUGS.pdf	8338284 09911e889c8d5a51f2795fd5e51ec27b92e6 2aec	no	94
Warnings:					
Information:					
Total Files Size (in bytes):			28612455		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					